- Report
- March 2023
- 545 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- December 2022
- 566 Pages
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- August 2022
United States
From €1844EUR$1,940USD£1,549GBP
- Report
- August 2022
Global
From €1131EUR$1,190USD£950GBP
- Report
- August 2022
Global
From €941EUR$990USD£791GBP
- Drug Pipelines
- March 2021
Global
From €2377EUR$2,500USD£1,997GBP
- Report
- October 2023
- 146 Pages
Global
From €3353EUR$3,528USD£2,817GBP
€3945EUR$4,150USD£3,314GBP
- Report
- February 2024
- 94 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- February 2024
- 104 Pages
Global
From €3500EUR$3,944USD£3,043GBP
- Report
- March 2024
- 132 Pages
Global
From €903EUR$950USD£759GBP
Steatohepatitis drugs are used to treat non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These drugs are used to reduce inflammation, improve liver function, and reduce the risk of cirrhosis and liver cancer. They can also help to reduce the risk of cardiovascular disease. Commonly used steatohepatitis drugs include vitamin E, pioglitazone, obeticholic acid, and elafibranor.
These drugs are part of the larger market of liver and kidney disorder drugs, which also includes drugs used to treat hepatitis, cirrhosis, and other liver and kidney diseases.
Some companies in the steatohepatitis drugs market include Gilead Sciences, Intercept Pharmaceuticals, Allergan, Novartis, and Merck. Show Less Read more
